Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.43 CAD | 0.00% | -1.15% | -12.24% |
03-13 | Crescita Therapeutics Reports Q4 Net Loss of $0.01 Per Share | MT |
03-13 | Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on August 29, 2023. | CI |
Sales 2022 | 23.52M 17.2M | Sales 2023 | 17.52M 12.81M | Capitalization | 9.79M 7.16M |
---|---|---|---|---|---|
Net income 2022 | - 0 | Net income 2023 | -1M -731K | EV / Sales 2022 | 0.29 x |
Net cash position 2022 | 6.7M 4.9M | Net cash position 2023 | 8.13M 5.95M | EV / Sales 2023 | 0.09 x |
P/E ratio 2022 |
16.5
x | P/E ratio 2023 |
-4.9
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 89.65% |
1 week | -1.15% | ||
Current month | -4.44% | ||
1 month | -4.44% | ||
3 months | -20.37% | ||
6 months | -32.81% | ||
Current year | -12.24% |
Managers | Title | Age | Since |
---|---|---|---|
Serge Verreault
CEO | Chief Executive Officer | - | - |
Jose DaRocha
DFI | Director of Finance/CFO | - | 17-08-31 |
Daniel Chicoine
CHM | Chairman | 70 | 16-02-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | - | 16-02-29 | |
Daniel Chicoine
CHM | Chairman | 70 | 16-02-29 |
John London
BRD | Director/Board Member | - | 16-02-29 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 0.43 | 0.00% | 2,200 |
24-04-25 | 0.43 | -2.27% | 4,515 |
24-04-24 | 0.44 | 0.00% | 4,000 |
24-04-23 | 0.44 | +2.33% | 3,500 |
24-04-22 | 0.43 | -1.15% | 4,700 |
Delayed Quote Toronto S.E., April 26, 2024 at 03:59 pm
More quotes1st Jan change | Capi. | |
---|---|---|
-12.24% | 6.12M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- CTX Stock